Keeping everybody in the cycle
Companies have long engaged with governments, health authorities and civil society organizations on ways to improve access to health care. The challenge today, especially in light of the COVID-19 pandemic, is that these companies must become key stakeholders in the virtuous circle themselves, leading in the development of the new tools and technologies that are part of our DNA and daily work, and actively working to introduce and scale up their use.
And so, many companies are already engaged in important and synergistic relationships – with highly leverageable networks that encompass research institutions, pharma, biotech, labs, surveillance centers, public health authorities, and on-the-ground healthcare providers and practitioners.
The ESG goals at QIAGEN are fully integrated into annual business and financial objectives. They are essential to ensuring that QIAGEN’s “license to operate” is approved by stakeholders. These investments to resolve social and environmental problems are investments in the future of the company and in ways to improve the world.
As a leader in both Life Sciences and Molecular Diagnostics, we are deeply committed to widening access to affordable healthcare, ensuring that innovations being developed in academic and pharma labs around the world are translated into products that benefit patients in both industrialized countries and low-resource regions. No country should be left behind.